USPTO Allows Claims on Regulus miRNA Patent Application

The application, owned by Stanford University and exclusively licensed to Regulus, claims methods of antagonizing miR-181a to regulate immune response.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories